Royalty Pharma plc (RPRX) 은(는) 상장 기업입니다 헬스케어 섹터의 바이오 산업에서 운영. 본사 소재지는 New York City, NY, 미국. 현재 CEO는 Pablo Legorreta.
RPRX 을(를) 보유 IPO 날짜 2020-06-16, 75 명의 정규직 직원, 에 상장 NASDAQ Global Select, 시가총액 $20.92B.
Royalty Pharma plc is a biopharmaceutical royalty company that identifies, evaluates, and acquires royalty streams from innovative drug therapies across the United States. The company collaborates with academic institutions, research hospitals, biotechnology companies, and pharmaceutical firms to fund biopharmaceutical innovation. Its diversified portfolio includes royalties on approximately 35 marketed therapies and 10 development-stage product candidates spanning therapeutic areas such as rare disease, cancer, neurology, infectious disease, hematology, and diabetes. Founded in 1996 and headquartered in New York, Royalty Pharma generates revenue through its ownership of royalty interests in marketed drugs while supporting the advancement of new treatments.